Dynogen Pharmaceuticals, Inc.

Case Western Reserve University

Tensha Therapeutics, Inc.

Steven B Landau

Matthew Oliver Fraser

Paul J Tesar

Drew Adams

Cheryl L Miller

Edward C Burgard

Zita Hubler

Dharmaraja Allimuthu

Michael H Kagey

Matthew Elitt

Karl Bruce Thor

A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.

Compounds and methods of promoting myelination

A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of &#x394;8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.

The present invention relates to treatment of a condition associated with hyperinsulinaemia using the compounds described herein.

Treatment of conditions associated with hyperinsulinaemia

The invention is a method of treating a subject with primary progressive or secondary progressive multiple sclerosis. The method comprises administering an effect amount of Cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop-2-enylamine or a pharmaceutically acceptable salt thereof to the subject.

The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using the compounds and pharmaceutical compositions described. (Formula (I)) 

Bromodomain inhibitors

A method is provided for using Cav2.2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.

Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

Method of treating lower urinary tract disorders

Methods are disclosed for the treatment of nausea and vomiting in a patient suffering therefrom comprising administering 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.

Method of treating nausea, vomiting, retching or any combination thereof

The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.

Growing community of inventors

Wellesley, MA, United States of America

Steven B Landau